Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.65 |
| ▸ | CA1 | P00915 | 7/20 | 0.65 |
| ▸ | CA2 | P00918 | 7/20 | 0.65 |
| ▸ | CA6 | P23280 | 7/20 | 0.65 |
| ▸ | CA7 | P43166 | 7/20 | 0.65 |
| ▸ | CA9 | Q16790 | 7/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.65 |
| ▸ | CA5A | P35218 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.65 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.65 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.65 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 8/20 | 0.54 |
| ▸ | CA3 | P07451 | 6/20 | 0.53 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12508290 | 0.92 | CA12 (0.64) | CA12CA1CA2CA6CA7 | |
| SCHEMBL29436058 | 0.86 | CA12 (0.69) | CA12CA1CA2CA6CA7 | |
| SCHEMBL14369223 | 0.85 | CA12 (0.74) | CA12CA1CA2CA6CA7 | |
| SCHEMBL11830205 | 0.84 | APP (0.62) | CA12CA1CA2CA6CA7 | |
| Furosemide SCHEMBL232277 | 0.83 | CISD1 (0.77) | CA12CA1CA2CA6CA7 | |
| SCHEMBL4416102 | 0.83 | CA12 (0.77) | CA12CA1CA2CA6CA7 | |
| SCHEMBL2880507 | 0.83 | CA12 (0.73) | CA12CA1CA2CA6CA7 | |
| SCHEMBL29436031 | 0.82 | CA12 (0.76) | CA12CA1CA2CA6CA7 | |
| SCHEMBL10837475 | 0.82 | CA12 (0.82) | CA12CA1CA2CA6CA7 | |
| SCHEMBL29436046 | 0.81 | CA1 (0.79) | CA12CA1CA2CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2389371-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA12 1338/4885CA1 988/4885CA2 489/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA12 1444/4885CA1 1022/4885CA2 471/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA12 1338/4885CA1 988/4885CA2 489/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | CA12 1049/4885CA1 701/4885CA2 388/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | CA12 2528/4885CA1 1755/4885CA2 1572/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA12 2583/4885CA1 1762/4885CA2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.